1. PIPC Chairman Tony Coelho Quoted In News On Disabilities, click here to view the article.
2. PCORI: Research Prioritization Topic Briefs, click here to view the paper.
3. PCORI Blog: The Best of Intentions: PCORI Invites Full Proposals Under First Round of Pragmatic Studies Initiative, click here to view the post.
4. AcademyHealth: Value-Based Insurance Design Can Increase Value Without Saving Money, click here to view the article.
5. Deloitte Insights: What It Takes to Compete on Value, Not Volume, click here to view the article.
6. NYT: Looking for the Final Word on Treatment, click here to view the article.
In a recent article published in the HeraldNet, PIPC Chairman Tony Coelho was quoted with respect to changes to regulations made by the Department of Labor. New rules implementing a section of the federal Rehabilitation Act now prohibit discrimination on the basis of disabilities. "Because of the new regulations, up to 465,000 people living with a disability may have a chance at gaining employment within the next year, according to Tony Coelho, the primary sponsor of the Americans with Disabilities Act and former California congressman. The act, which prohibits discrimination based on disability, was enacted by Congress in 1990. 'In my view, it’s a real game-changer,' Coelho said. 'For those of us with disabilities, a job is what’s critical.'" Click here to view the article.
2. PCORI: Research Prioritization Topic Briefs
Recently, the Patient-Centered Outcomes Research Institute (PCORI) released a paper that included four topic briefs regarding health disparities experienced by certain populations. Topics include: Improving the Continuum of Care for Patients with Disabilities; Interventions to Promote Tobacco Cessation Among Vulnerable Populations; Quality of Care for LGBT Populations; Interventions to Reduce Disparities in the Efficacy of Treatments for Sleep Disorders. Click here to view the paper.
3. PCORI Blog: The Best of Intentions: PCORI Invites Full Proposals Under First Round of Pragmatic Studies Initiative
Joe Selby, Executive Director of the Patient-Centered Outcomes Research Institute (PCORI), penned a blog last week calling for new proposals. “Full applications for this first round of pragmatic clinical studies are due August 8 […] As compared to our previously funded randomized controlled trials, studies in the new category include broader and more diverse populations, are conducted in routine clinical care settings, are often simpler and larger, and are intended to provide information that can be directly adopted by healthcare providers.” Click here to view the post.
4. AcademyHealth: Value-Based Insurance Design Can Increase Value Without Saving Money
Dr. Austin Frakt and Dr. Aaron Carroll of The Incidental Economist published a post on the AcademyHealth Blog last week regarding VBID. “It would be especially valuable and impressive if a change in medication utilization could more than pay for itself through a reduction in non-drug utilization. However, it would be unwise to judge VBID by this criterion alone. If medications at least partly substitute for or delay utilization with potentially higher chances of complications and life disruption (e.g., surgery), that may be a substitution worth making even if it doesn't save money to the health system.” Click here to view the article.
5. Deloitte Insights: What It Takes to Compete on Value, Not Volume
In a sponsored column for the Wall Street Journal, Deloitte Insights reported on the nuances of value-based payments versus fee for service via comparative effectiveness research. “[Terry Hisey, vice chairman and U.S. Life Sciences sector leader at Deloitte LLP:] CFOs can help align company strategies to the changing market dynamics by employing a comparative effectiveness approach to deciding where to invest and grow the business. It's a strategic approach that puts the spotlight on winning the value argument because it's about accessing and synthesizing real-world evidence to inform strategic decisions. Taking a comparative effectiveness approach to product development decisions means looking at how a product performs in the real world, compared to competing products, not in double-blind, placebo-controlled clinical trials.” Click here to view the article.
6. NYT: Looking for the Final Word on Treatment
Dr. Kent A. Sepkowitz of The New York Times reported last week about the need for patient-centered outcome reviews. He commented, “there are perhaps hundreds of routine tests, treatments and procedures for which the best approach has not been defined: screening for prostate or breast cancer, for example, or even something as seemingly simple as preventing colds. Flip-flopping creates uncertainty not just for patients, but for the medical profession itself. So what is a well-intentioned, hard-working doctor to do when the available evidence is inconclusive? Thankfully, there's a solution. It's called the systematic review, and it is increasingly important in day-to-day patient care.” Click here to view the article.